首页 News 正文

Lilly: We have applied to the FDA for the weight loss drug Zepbound to treat sleep apnea, and it is expected to be approved as early as the end of the year

houhou
4050 0 0

According to AI News, according to CNBC, Lilly has applied to the United States for approval of its weight loss drug Zepbound for the treatment of the most common sleep related respiratory disorders, and regulatory agencies are expected to make a decision as early as the end of this year. The company released additional data from two later trials, showing that Zepbound helped alleviate obstructive sleep apnea in nearly half of patients.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

houhou 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    0